That's important, due to the fact that the method a protein in the body folds determines if a pharmaceutical will have the ability to bind to that protein and work. Simply put, we have to understand how these proteins fold if we desire a drug to work. Historically, this has actually been an experimental procedure (jeff brown prediction). Now, Alpha, Fold can anticipate protein folding with 92. 4% precision. That's going to make it much simpler to create drugs that do what they're created to do. This was a development almost nobody observed. But it's going to have profound ramifications for treating disease. I forecast that Alpha, Fold will be 98% accurate by the end of 2021.
And, of course, there will be lots of financial investment opportunities in this space, too. Moving topics It's going to be a great year for bitcoin. I'm bullish on it in 2021 (diplomatic relations). That stated, I still believe bitcoin will continue to be unpredictable. We're close to all-time highs. I wouldn't be shocked if it drew back maybe considerably before going higher - future report review. I have actually been covering bitcoin for a very long time now. One of the very first research reports I ever released was on bitcoin. That remained in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $34,000 today.
But at the time of that initial recommendation, I entitled my report "What's the Big Offer With Bitcoin?" That shows you where the discussion was at the time. We were mostly educating readers. However that's not the big concern any longer. Now we're seeing institutional money finally take an interest in bitcoin. Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some little, niche enterprise. Mass, Mutual is a relied on 170-year-old institution. So think of that. In 5 years, we went from educating readers on what bitcoin is to a business like Mass, Mutual taking a $100 million stake.
And that's a big factor I'm bullish on it this year. jeff brown investment prediction. Regards, Jeff Brown, Editor, The Bleeding Edge I have a perk prediction 2020 was a record year for IPOs. 552 U.S. business went public the most in more than twenty years. These companies raised an overall of $172 billion. That's an all-time high beating the previous yearly record by 43%. I anticipate 2021 will be another record year in IPOs. There are a lot of excellent personal companies on the edge of striking the public markets And I've been dealing with a brand-new way for you to invest even prior to these companies go public.
This chance has been building over the last few years. I can't wait to inform you all about it. Join me tomorrow at 8 p. m. ET for my Pre-IPO Code Event to learn all the information. Go right here to book your area free of charge.
Emma Walsh here, handling editor of the Diary. Routine Diary readers know that tech isn't our usual beat (future report). And when it comes to tech investing, we leave it to the professionals. Luckily, we have a number of such specialists in our Rolodex. Our associate Jeff Brown will be familiar to our longtime readers. He is one of the most accomplished tech investing experts we know (jeff brown 2021 predictions). In reality, he had several triple-digit returns in his Brownstone Research study portfolios in 2015. Here's what Jeff thinks the tech sector will bring us in 2021 Each year, I like to have a look at the huge image and predict what's simply around the corner.
That includes things like 5G networks, biotech, artificial intelligence, and a lot more. These trends are experiencing rapid growth and producing incredible opportunities for investors. I desire to make certain all our readers are prepared for what's next. And with that in mind, let me draw the image of what I see being available in the next 12 months Our brand-new 5G (fifth-generation) cordless networks are a topic I have actually been covering for years now. jeff brown genetic sequencer stock. However regardless of what many readers might think, this is a pattern that's simply getting going. Although the COVID-19 pandemic disrupted supply chains in 2015, a remarkable 250 million 5G-enabled devices were still sold.
And all of this ultimately led to Apple postponing the release of the 5G-enabled i, Phone 12 by 2 months (the legacy report predictions). Losing two months of manufacturing and sales truly affects the number of 5G devices are sold in the calendar year. When you think about all of that, offering 250 million systems is exceptional. More significantly, the delays triggered by the pandemic produced a lots of bottled-up demand. Which need is now going to be pressed into 2021. In reality, I anticipate that more than 500 million 5G gadgets will be shipped in 2021 - exponential tech investor. Which's not my only 5G prediction When I've talked about 5G in the past, I have actually described its 3 different stages.
In Stage 2, 5G gadgets go on sale. 5G phones and other products start to reach consumers. And in Stage 3, 5G services start to be provided (tech predictions). That's when we start to see applications running on 5G networks. Think about things like huge multiplayer video games over a cellphone. That's not possible with 4G. It will be with 5G. And my second 5G forecast for 2021 is that we will begin Phase Three by this summer season. This begins something of a virtuous cycle: Many individuals don't actually appreciate the technology. But they will care if there are interesting applications that can just be accessed with a 5G phone.
That leads to more 5G apps being established. In truth, 5G is going to open a suite of extraordinary applications: self-driving automobiles, the Internet of Things, robotic surgery, and more. All of these technologies need 5G. The financial investment opportunities moving forward will be massive. Stepping far from 5G, the next crucial innovation I anticipate in 2021 is CRISPR genetic editing. CRISPR stands for "clustered frequently interspaced brief palindromic repeat." It's a mouthful. However it is among the most amazing advancements in biotechnology. At a high level, CRISPR is an innovation that can modify our genetic makeup as if it were software.
The program can crash or not operate correctly. CRISPR utilizes a similar concept but with our genetic code. "Typos" in our genome can result in disease. CRISPR can fix these "typos." For several years, CRISPR was mostly a specific niche technology that wasn't well understood. And throughout that time, there were really only three companies running in this area. However things are changing. CRISPR is no longer just theoretical. We're seeing actual outcomes. We're dealing with diseases and seeing that this innovation simply works. And as an outcome, a "2nd crop" of early-stage CRISPR business is going public and delivering incredible returns. This entire market is successfully a greenfield chance.
There's space for lots of companies to exist in this area. tech stock. And there will be more. That's my prediction for CRISPR in 2021. I forecast that two or three more genetic modifying companies will hold their IPOs. Sticking with biotechnology, we are seeing amazing things taking place at the merging of biotech and expert system (AI). Google's AI subsidiary, Deep, Mind, simply revealed at the end of 2020 that its newest Alpha, Fold software application can accurately predict the folding of a protein based solely on its amino acid sequence with 92. 4% accuracy. That is very important because the way a protein in the human body folds determines if a pharmaceutical will have the ability to bind to that protein and work.
Historically, this has actually been an experimental procedure. However now, Alpha, Fold can predict protein folding with 92. 4% precision. That's going to make it a lot easier to create drugs that do what they're developed to do. And here's my next prediction. I predict that Alpha, Fold will be 98% accurate by the end of 2021. And we will see not just one but several drug therapies produced utilizing this innovation. This was one of those developments that nearly nobody observed. But it's going to have profound ramifications for curing illness. And, naturally, there will be lots of investment chances in this space, too.
It's going to be an excellent year for bitcoin. I'm bullish on it in 2021. That said, I still believe bitcoin will continue to be volatile. We're close to all-time highs. I would not be amazed if it drew back perhaps considerably prior to going greater. I've been covering bitcoin for a long period of time now. Among the first research study reports I ever released was on bitcoin - jeff brown biotech genome sequencing. That was in June 2015. At the time, bitcoin was trading for about $240. Bitcoin trades for over $40,000 today. So that's a 16,500%+ return on financial investment for any person who followed my recommendation. However at the time of that initial recommendation, I titled my report, "What's the Big Deal With Bitcoin?" That reveals you where the discussion was at the time.
But no one is asking that concern anymore. Now, we're seeing institutional cash finally taking an interest in bitcoin. The huge news was that Massachusetts Mutual Life Insurance coverage took a $100 million stake in bitcoin in December. This is not some small, specific niche business. tech stock. Mass, Mutual is a 150-year-old institution. So think of that. In five years, we went from educating readers on what bitcoin is to a company like Mass, Mutual taking a $100 million stake. The institutional adoption of bitcoin will continue. And that's a big reason I'm bullish on it this year. Regards, Jeff Brown, Editor, The Bleeding Edge I have one more benefit prediction In 2021, we're going to have another record year in IPOs. One website reports that Jeff Brown is worth about $27. 5 million and claims the details depends on date since February 2021, however we could not individually confirm this claim. Provided Jeff Brown's past, he likely has a considerable net worth, however we can't hammer down an exact figure at this moment. Brown is best known for his sage-like ability to pick winning innovation stocks. He spent more than 25 years investigating innovation companies like Qualcomm, NXP semiconductors, and Juniper Networks. Brown's substantial experience gives him an excellent perspective on the marketplace. He's constantly on the hunt for brand-new opportunities, and he shares a number of his best choices in the Near Future Report.
That's high appreciation, but it's not ridiculously reasoned. Brown has an excellent track record as a stock-picker, and he successfully anticipated a few of the greatest financial events of the past twenty years. Although he does not appear to launch his choices to the general public, the service's success is a direct indicator of Brown's stock-picking expertise. Nobody on Wall Street gets it ideal each time, however Jeff Brown's accurate predictions have actually earned him legions of devoted fans. That says a lot about his ability. The Near Future Report is released by Brownstone Research, a popular financial research publisher. Brownstone Research study uses a number of research services with a broad variety of expertises - tech stock.
The company is also connected with Bonner & Partners, another well-respected research study publisher - artificial intelligence. On its website, Brownstone says its objective is to provide retail financiers with professional-grade research: "For too long, the best financial investment research study has actually not been readily available to specific financiers. It has actually been usually booked for financial investment banks, hedge funds, private equity, and high-net-worth customers. brownstone research. The objective of Brownstone Research study is to make that type of exclusive research study readily available to any financiers wanting to gain an edge in the markets. The goal is easy to provide special and successful investment research study discovered no place else." -Brownstone Research study site excerpt from the Jeff Brown is the creator of Brownstone Research study, and he likewise works as the company's Chief Financial investment Expert.
With Brown assisting the ship, Brownstone Research is a powerhouse publisher with lots to offer its clients. After years of stable success at the helm of top-tier companies like Tesla and Space, X, Elon Musk is a family name throughout most of America. If you know even a bit about the marketplace, you know that he has a track record as a King Midas of sorts. second wave. Everything he touches relies on gold! Jeff is well mindful of Elon Musk's executive expertise, so he constantly has an eye out for the Silicon Valley rock star's next relocation. This time, Jeff has an early lead on Elon's next big job.
In reality, Brown believes S.A.V. jeff brown genetic sequencer stock. might be "the most significant pattern of the 2020s, and he's not alone. Inspect out these quotes from other widely known S.A.V. bulls: Elon's next big act will be marrying two advanced innovations: artificial intelligence and electric cars. Musk hopes the mix will help him establish the first fully-autonomous, self-driving automobiles ever. It's nothing brief of the automotive market's Holy Grail. As you know, electric vehicles and self-driving vehicle stocks have actually been huge this year, however the Wall Street maker has actually been huge on hype without much concrete outcome. In spite of a drastic boost in competitors over the previous couple of years, Brown still believes Musk has the best possibility of putting all of it together.
tech could be the magic string that ties it all together. S.A.V. stands for Shared Autonomous Car, and it could be the future of transportation. Generally, this innovation would allow you to lease out your vehicle as an autonomous, self-driving taxi when you're not utilizing it. You simply leave the vehicle and press a button on an app that tells the vehicle to "sign up with the fleet." Next thing you know, you're relaxing on your sofa while your vehicle shuttles ride-sharers around town. Most importantly, you get to keep a hefty chunk of the earnings. It sounds insane, but it could be closed than you think.